Journal article
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Authors
Tutt ANJ; Garber J; Gelber RD; Phillips K-A; Eisen A; Johannsson OT; Rastogi P; Cui KY; Im S-A; Yerushalmi R
Journal
Annals of Oncology, Vol. 33, No. 5, pp. 566–568
Publisher
Elsevier
Publication Date
5 2022
DOI
10.1016/j.annonc.2022.03.008
ISSN
0923-7534